Search
Repare Therapeutics Inc
RPTXAdd to Watchlist
2.650USD
0.0000.00%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
114.24MMarket Cap
LossP/E TTM
More Details of Repare Therapeutics Inc Company
Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes RP-3467, a Phase 1 Polo ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor, and lunresertib, a PKMYT1 inhibitor.
Repare Therapeutics Inc Info
Ticker SymbolRPTX
Company nameRepare Therapeutics Inc
IPO dateJun 19, 2020
CEOForte (Steve)
Number of employees129
Security typeOrdinary Share
Fiscal year-endJun 19
Address7210 Frederick-Banting, Suite 100
CityST-LAURENT
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryCanada
Postal codeH4S 2A1
Phone18574127018
Websitehttps://www.reparerx.com/
Ticker SymbolRPTX
IPO dateJun 19, 2020
CEOForte (Steve)
Company Executives of Repare Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Michael Zinda, Ph.D.
Dr. Michael Zinda, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
48.78K
--
Mr. Steve Forte
Mr. Steve Forte
President, Chief Executive Officer, Chief Financial Officer, Director
President, Chief Executive Officer, Chief Financial Officer, Director
25.28K
--
Ms. Sandra Alves
Ms. Sandra Alves
Senior Vice President, Chief Accounting Officer
Senior Vice President, Chief Accounting Officer
12.82K
-146.62%
Ms. Carol Anne Schafer
Ms. Carol Anne Schafer
Independent Director
Independent Director
--
-100.00%
Dr. David P. Bonita, M.D.
Dr. David P. Bonita, M.D.
Independent Director
Independent Director
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Independent Director
Independent Director
--
--
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
--
-100.00%
Mr. Thomas Civik
Mr. Thomas Civik
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Dr. Susan M. Molineaux, Ph.D.
Dr. Susan M. Molineaux, Ph.D.
Independent Director
Independent Director
--
--
Dr. Steven H. Stein, M.D.
Dr. Steven H. Stein, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Michael Zinda, Ph.D.
Dr. Michael Zinda, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
48.78K
--
Mr. Steve Forte
Mr. Steve Forte
President, Chief Executive Officer, Chief Financial Officer, Director
President, Chief Executive Officer, Chief Financial Officer, Director
25.28K
--
Ms. Sandra Alves
Ms. Sandra Alves
Senior Vice President, Chief Accounting Officer
Senior Vice President, Chief Accounting Officer
12.82K
-146.62%
Ms. Carol Anne Schafer
Ms. Carol Anne Schafer
Independent Director
Independent Director
--
-100.00%
Dr. David P. Bonita, M.D.
Dr. David P. Bonita, M.D.
Independent Director
Independent Director
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Repare Therapeutics Inc?
The top five shareholders of Repare Therapeutics Inc are: Dr. Michael Zinda, Ph.D.
How many institutions hold shares of Repare Therapeutics Inc (RPTX)?
As of 2025Q4, 116 institutions hold shares of Repare Therapeutics Inc, with a combined market value of approximately 24.72M, accounting for 57.35% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -9601917.00.